CSF1R and Hodgkins lymphoma: CSF1R inhibitors have already been studied in several human diseases and JNJ-40346527 proved ineffective in Phase 2 trials for rheumatoid arthritis (Genovese et al., 2015), Crohn’s disease (Provention Bio press release, 2019), and Hodgkin’s lymphoma (von Tresckow et al., 2015).